期刊
CURRENT OPINION IN IMMUNOLOGY
卷 15, 期 2, 页码 138-147出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/S0952-7915(03)00015-3
关键词
-
类别
A novel approach to vaccination against cancer is to exploit dendritic cells (DCs) as 'nature's adjuvants' and actively immunize cancer patients with a sample of their own DCs primed with tumor antigens. DC vaccination is, however, still at an early stage, slowed in part by the need to carry out research in humans. Nevertheless, valuable proofs of concept have been obtained with respect to the capacity of DCs to expand cancer-directed immune responses. The methods for preparing DCs are being improved continuously, and there are many opportunities to improve efficacy at the level of DC biology. An increased number of Phase I, II and III studies will drive this new area of human research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据